Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free RGC Stock Alerts

Regencell Bioscience (RGC) Financials

Regencell Bioscience logo
$28.58 +1.67 (+6.21%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$28.03 -0.55 (-1.92%)
As of 05/15/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Regencell Bioscience

Annual Income Statements for Regencell Bioscience

This table shows Regencell Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.39 0.81 -1.35 -7.45 -5.96 -4.26 -3.60
Consolidated Net Income / (Loss)		 -0.39 -0.81 -1.35 -7.59 -6.06 -4.36 -3.58
Net Income / (Loss) Continuing Operations		 -0.39 -0.81 -1.35 -7.59 -6.06 -4.36 -3.58
Total Pre-Tax Income 		-0.39 -0.81 -1.35 -7.59 -6.06 -4.36 -3.58
Total Operating Income		 -0.39 -0.81 -1.38 -7.62 -6.27 -4.74 -3.77
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 0.39 0.81 1.38 7.62 6.27 4.74 3.77
Selling, General & Admin Expense		 0.16 0.31 0.94 5.08 4.43 3.55 2.81
Marketing Expense		 0.00 0.11 0.00 0.03 0.26 0.13 0.01
Research & Development Expense		 0.23 0.39 0.44 2.51 1.58 1.07 0.95
Total Other Income / (Expense), net		 0.00 0.00 0.03 0.00 0.21 0.37 0.19
Other Income / (Expense), net		 - - 0.03 - 0.21 0.37 0.19
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 0.00 -0.15 -0.19 -0.06 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - 0.00 0.09 -0.04 0.02
Basic Earnings per Share		 - $0.08 $0.13 ($0.58) ($1.19) ($0.87) ($0.72)
Weighted Average Basic Shares Outstanding		 0.04 10M 10M 12.81M 494.49M 494.49M 494.49M
Diluted Earnings per Share		 - - - ($0.58) ($1.19) ($0.87) ($0.72)
Weighted Average Diluted Shares Outstanding		 10M 10M 10M 12.81M 494.49M 494.49M 494.49M
Weighted Average Basic & Diluted Shares Outstanding		 10M 10M 10M 13.01M 13.01M 13.01M 494.49M

Quarterly Income Statements for Regencell Bioscience

No quarterly income statements for Regencell Bioscience are available.

Annual Cash Flow Statements for Regencell Bioscience

This table details how cash moves in and out of Regencell Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 0.09 0.14 -0.33 6.36 -4.85 1.40 -0.54
Net Cash From Operating Activities		 -0.39 -0.73 -0.77 -5.27 -4.96 -4.00 -3.11
Net Cash From Continuing Operating Activities		 -0.39 -0.73 -0.77 -5.20 -4.96 -4.00 -3.11
Net Income / (Loss) Continuing Operations		 -0.39 -0.81 -1.35 -7.59 -6.06 -4.36 -3.58
Consolidated Net Income / (Loss)		 -0.39 -0.81 -1.35 -7.59 -6.06 -4.36 -3.58
Depreciation Expense		 0.00 0.01 0.03 0.15 0.29 0.31 0.08
Amortization Expense		 - 0.00 0.00 0.45 0.48 0.44 0.32
Non-Cash Adjustments To Reconcile Net Income		 - 0.00 0.08 2.75 0.83 0.20 0.06
Changes in Operating Assets and Liabilities, net		 0.00 0.08 0.47 -0.96 -0.50 -0.58 0.02
Net Cash From Investing Activities		 0.00 -0.12 0.00 -11 0.06 5.24 2.69
Net Cash From Continuing Investing Activities		 0.00 -0.12 0.00 -11 0.06 5.24 2.69
Purchase of Property, Plant & Equipment		 0.00 -0.12 0.00 -0.78 -0.03 -0.01 -0.15
Purchase of Investments		 - 0.00 0.00 -10 -10 -5.00 -32
Sale of Property, Plant & Equipment		 - - 0.00 0.00 0.00 0.00 0.00
Sale and/or Maturity of Investments		 - - 0.00 0.00 10 10 35
Net Cash From Financing Activities		 0.48 0.99 0.44 22 0.13 0.10 0.00
Net Cash From Continuing Financing Activities		 0.48 0.99 0.44 22 0.13 0.10 0.00
Issuance of Common Equity		 - 0.00 0.00 23 0.13 0.10 0.00
Effect of Exchange Rate Changes		 - - - 0.00 - - -0.11
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Regencell Bioscience

No quarterly cash flow statements for Regencell Bioscience are available.

Annual Balance Sheets for Regencell Bioscience

This table presents Regencell Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 0.51 0.34 18 13 8.44 5.76
Total Current Assets		 0.39 0.07 16 12 8.11 4.90
Cash & Equivalents		 0.39 0.06 6.42 1.56 2.96 2.42
Short-Term Investments		 - 0.00 10 10 5.00 2.48
Prepaid Expenses		 0.00 0.01 0.03 0.06 0.15 0.01
Plant, Property, & Equipment, net		 0.11 0.08 0.71 0.44 0.14 0.22
Total Noncurrent Assets		 0.02 0.19 0.86 0.56 0.18 0.64
Other Noncurrent Operating Assets		 0.02 0.19 0.86 0.56 0.18 0.64
Total Liabilities & Shareholders' Equity		 0.51 0.34 18 13 8.44 5.76
Total Liabilities		 3.16 4.34 0.94 0.63 0.22 0.90
Total Current Liabilities		 3.16 4.34 0.58 0.61 0.19 0.66
Short-Term Debt		 3.07 3.68 0.02 0.01 0.01 0.00
Accrued Expenses		 0.10 0.57 0.15 0.16 0.13 0.35
Other Current Liabilities		 - 0.00 0.41 0.44 0.06 0.31
Total Noncurrent Liabilities		 0.00 0.00 0.36 0.03 0.03 0.23
Other Noncurrent Operating Liabilities		 - 0.00 0.36 0.03 0.03 0.23
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -2.65 -4.00 17 12 8.22 4.86
Total Preferred & Common Equity		 -2.65 -4.00 17 12 8.22 4.86
Total Common Equity		 -2.65 -4.00 17 12 8.22 4.86
Common Stock		 0.00 0.00 29 29 30 30
Retained Earnings		 -2.65 -4.00 -11 -17 -22 -25
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.09 -0.05 -0.06
Noncontrolling Interest		 - 0.00 0.02 -0.04 0.00 0.00

Quarterly Balance Sheets for Regencell Bioscience

No quarterly balance sheets for Regencell Bioscience are available.

Annual Metrics And Ratios for Regencell Bioscience

This table displays calculated financial ratios and metrics derived from Regencell Bioscience's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -105.34% -64.45% -431.20% 24.54% 31.65% 11.78%
EBIT Growth		 0.00% -107.77% -65.78% -465.64% 20.42% 28.03% 17.85%
NOPAT Growth		 0.00% -107.77% -70.04% -451.47% 17.64% 24.50% 20.41%
Net Income Growth		 0.00% -107.77% -65.78% -463.92% -57.13% 27.39% 17.85%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 22.41% 26.67% 17.24%
Operating Cash Flow Growth		 0.00% -85.83% -5.61% -586.43% 5.77% 19.37% 22.19%
Free Cash Flow Firm Growth		 0.00% 0.00% 6.80% -1,040.89% 35.07% 24.13% 25.67%
Invested Capital Growth		 0.00% 0.00% -1,270.70% 281.17% -35.96% -38.90% -112.86%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 196.85% 198.59% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 99.70% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 30.65% 40.51% -116.10% -82.10% -85.76% -54.81%
Cash Return on Invested Capital (CROIC)		 0.00% -3,749.80% 0.00% -939.91% -744.07% -897.54% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 30.65% 40.51% -115.96% -82.17% -85.93% -54.81%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 30.65% 33.69% -44.50% -99.19% -105.43% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.27 -0.57 -0.97 -5.33 -4.39 -3.32 -2.64
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 18.17% 12.05% -35.40% -53.96% -54.85% -14.71%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -54.27%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -0.39 -0.81 -1.35 -7.62 -6.06 -4.36 -3.58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.39 -0.80 -1.32 -7.01 -5.29 -3.62 -3.19
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 20.28 24.92 5.32 1,733.67
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 20.28 24.92 5.32 1,733.67
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 65.09 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 1.54% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1,734.13 0.00 485.13 662.26 134.52 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 -1.16 -0.92 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.01 -0.95 -0.98 -0.96 -0.97 -0.98
Leverage Ratio		 0.00 -0.19 -0.13 1.40 1.05 1.04 1.09
Compound Leverage Factor		 0.00 -0.19 -0.13 1.40 1.05 1.04 1.09
Debt to Total Capital		 0.00% 732.64% -1,166.41% 0.09% 0.09% 0.10% 0.05%
Short-Term Debt to Total Capital		 0.00% 732.64% -1,166.41% 0.09% 0.09% 0.10% 0.05%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.09% -0.34% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -632.64% 1,266.41% 99.82% 100.25% 99.90% 99.95%
Debt to EBITDA		 0.00 -3.82 -2.79 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 -3.34 -2.74 2.34 2.18 2.20 1.53
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -5.40 -3.81 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 -4.72 -3.75 3.08 2.63 2.40 1.85
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -8.90 -37.28 220.12 282.03 115.34 5,639.53
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.12% -0.09% -0.20% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 0.12 0.02 28.46 19.15 41.92 7.39
Quick Ratio		 0.00 0.12 0.01 28.41 19.06 41.13 7.38
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -0.60 -0.56 -6.39 -4.15 -3.15 -2.34
Operating Cash Flow to CapEx		 0.00% -616.59% 0.00% -674.51% -18,783.40% -74,436.14% -2,039.16%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 0.03 -0.38 0.68 0.44 0.27 -0.03
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.03 -0.41 1.05 -0.24 -0.17 -0.30
Enterprise Value (EV)		 0.00 56 56 330 288 36 8,421
Market Capitalization		 53 53 53 346 300 44 8,426
Book Value per Share		 $0.00 ($0.27) ($0.40) $1.71 $0.92 $0.63 $0.01
Tangible Book Value per Share		 $0.00 ($0.27) ($0.40) $1.71 $0.92 $0.63 $0.01
Total Capital		 0.00 0.42 -0.32 17 12 8.23 4.86
Total Debt		 0.00 3.07 3.68 0.02 0.01 0.01 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 2.68 3.62 -16 -12 -7.95 -4.89
Capital Expenditures (CapEx)		 0.00 0.12 0.00 0.78 0.03 0.01 0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -0.10 -0.65 -0.53 -0.54 -0.03 -0.66
Debt-free Net Working Capital (DFNWC)		 0.00 0.29 -0.59 16 11 7.93 4.24
Net Working Capital (NWC)		 0.00 -2.78 -4.27 16 11 7.92 4.24
Net Nonoperating Expense (NNE)		 0.12 0.24 0.38 2.26 7.54 5.35 0.95
Net Nonoperating Obligations (NNO)		 0.00 2.68 3.62 -16 -12 -7.95 -4.89
Total Depreciation and Amortization (D&A)		 0.00 0.01 0.03 0.60 0.77 0.75 0.39
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.58 $0.45 ($0.33) ($0.72)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 12.81M 13.01M 13.01M 494.49M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.33) ($0.72)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 10M 13.01M 13.01M 13.01M 494.49M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 10M 13.01M 13.01M 13.01M 494.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.27 -0.57 -0.97 -5.33 -4.39 -3.32 -2.64
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -12.79% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Regencell Bioscience

No quarterly metrics and ratios for Regencell Bioscience are available.


Financials Breakdown Chart

Regencell Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Regencell Bioscience's financial year ends in June. Their financial year 2025 ended on June 30, 2025.

Regencell Bioscience's net income appears to be on an upward trend, with a most recent value of -$3.58 million in 2025, rising from -$390.99 thousand in 2019. The previous period was -$4.36 million in 2024. Find out what analysts predict for Regencell Bioscience in the coming months.

Regencell Bioscience's total operating income in 2025 was -$3.77 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $3.77 million

Over the last 6 years, Regencell Bioscience's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Regencell Bioscience's total liabilities were at $895.31 thousand at the end of 2025, a 307.9% increase from 2024, and a 71.7% decrease since 2020.

In the past 5 years, Regencell Bioscience's cash and equivalents has ranged from $59.41 thousand in 2021 to $6.42 million in 2022, and is currently $2.42 million as of their latest financial filing in 2025.

Over the last 6 years, Regencell Bioscience's book value per share changed from 0.00 in 2019 to 0.01 in 2025, a change of 1.0%.


Related Companies

Financial statements for NASDAQ:RGC last updated on 11/14/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX Goes Public. Here's What Happens To Your IRA.
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel